About

Phare Pharma is a pharmaceutical input manufacturer specializing in EU-GMP certified active pharmaceutical ingredients (APIs) derived from cannabis. Headquartered in Kalamata, Greece, Phare holds one of the country's largest medical cannabis licenses and is positioned to begin facility construction immediately upon capitalization. Our mandate is the production of standardized, traceable, solventless cannabis-based APIs, serving licensed pharmaceutical manufacturers and distributors across Europe, Australia, and other regulated markets. Phare is not a speculative venture—it is a pharmaceutical infrastructure project. Facility designs are complete, GACP construction permits are secured, and regulatory pathways to EU-GMP certification are mapped with specialized consultants. All key systems, contracted teams, and global supply chain partnerships are prepared for execution. Phare’s production includes EU-GMP cannabis flower and solventless cannabinoid concentrates. Extraction uses only mechanical and aqueous methods, preserving the full spectrum of therapeutic compounds without chemical solvents, providing pharmaceutical partners with clean, high-purity inputs aligned to stringent medicinal standards.

Solution & Product

Phare Pharma addresses key challenges in Europe's emerging medical cannabis market by delivering standardized, compliant cannabinoid inputs for pharmaceutical use. We solve market fragmentation by offering domestically produced, EU-GMP certified APIs aligned with regulatory standards, improving supply chain security for manufacturers and healthcare providers. Our focus on solventless extraction ensures cleaner, safer products with enhanced preservation of cannabinoids, terpenes, and flavonoids critical for therapeutic efficacy. Phare’s products provide manufacturers and formulators with reliable access to full-spectrum inputs, increasing treatment options for patients and strengthening pharmaceutical supply chains. We target specialized markets by cultivating high-potency flower and developing solventless concentrates using proprietary genetics. By combining local production, regulatory adherence, and technology-driven quality control, Phare improves patient access to high-quality cannabinoid-based therapies and provides the infrastructure needed to support Europe's rapidly growing medical cannabis market sustainably.

Innovation & Scalability

Phare Pharma’s production platform integrates advanced cultivation technology and solventless extraction systems to meet pharmaceutical standards. Cultivation areas use Horti-Coolers arranged in a checkerboard configuration, ensuring localized, AI-driven control over humidity, airflow, and temperature, eliminating microclimates and optimizing uniformity across production zones. This cultivation design, rare in cannabis operations, supports consistent yields and compound profiles critical for pharmaceutical formulations. Extraction operations exclusively use solventless methods, including ice water agitation and mechanical pressing (rosin extraction), maximizing the retention of full-spectrum therapeutic compounds without chemical solvents. Using equipment from Whistler Technologies, we produce pharmaceutical-grade bubble hash and rosin concentrates suitable for clinical applications. These methods preserve volatile terpenes and flavonoids essential for the entourage effect and higher therapeutic efficacy. Phare’s infrastructure is engineered for rapid scalability, compliance with evolving EU regulations, and long-term positioning as a leader in pharmaceutical cannabinoid production.

Traction & achievements

Phare Pharma has achieved critical milestones positioning us to meet the growing demand for clinical-grade cannabinoid APIs. We have secured prime agricultural land in Kalamata, obtained GACP and manufacturing permits from the Ministries of Agricultural Development and Development, and completed facility designs reviewed by third-party EU-GMP compliance consultants. Engineering planning is finalized, with supply chain vendors pre-selected and contracts prepared for execution. Letters of Intent have been signed with major pharmaceutical cannabis distributors, including Demecan and Drapalin, validating over 275 kg in annual demand. Our team has assembled a proprietary, pharmaceutical-grade genetic library tailored for high-yield, high-potency cultivation. Financial models and qualitative analyses confirm the project’s economic viability and operational resilience. Every aspect of design, cultivation, and processing aligns with EU-GMP and GACP standards. These achievements establish Phare Pharma as a fully licensed, market-ready supplier, offering a credible, compliant foundation for the development of Europe's cannabinoid pharmaceutical sector.

Team & Why Us

Phare Pharma is led by a multidisciplinary team with expertise in cannabis cultivation, solventless extraction, regulatory navigation, and facility development. Our leadership has successfully built and operated licensed cannabis ventures across North America under GACP and GMP-aligned protocols. We operate as a pharmaceutical input supplier, offering EU-GMP compliant cannabis flower and solventless concentrates to pharmaceutical manufacturers and licensed distributors. Our team specializes in optimizing controlled-environment agriculture, designing GACP-compliant operations, and deploying solventless extraction technologies aligned with clinical-grade production requirements. With contracted pharmaceutical consultants, proprietary genetics, and a jurisdictional strategy focused on regulated markets, Phare is positioned to deliver standardized, traceable cannabis APIs for clinical applications. Our infrastructure, licensing achievements, and operational readiness provide immediate access to high-barrier markets and support scalable expansion across Europe’s emerging cannabinoid pharmaceutical sector.

Funding Needs

Phare Pharma is raising €39 million through a structured three-tranche convertible note to fund construction, certification, and operational launch. Demand validation is already secured: formal Letters of Intent confirm annual commitments of 275+ kg from Demecan and Drapalin, two of Germany’s largest EU-GMP pharmaceutical cannabis importers. Active discussions are underway with partners in Australia, Switzerland, and Greece. The funding structure is: Tranche I (€14M): GACP cultivation facility construction and infrastructure Tranche II (€13M): EU-GMP manufacturing facility completion, certification, and staffing Tranche III (€12M): Operational launch, SOP development, and initial production cycles Over €2M has already been invested in non-dilutive capital for land acquisition, licensing, and regulatory preparation. Phare is a clinical-grade cannabinoid input manufacturer executed by a globally experienced team, fully aligned with EU pharmaceutical compliance, and strategically positioned to capitalize on supply chain, regulatory, and market trends across high-barrier jurisdictions.